Creating a management plan for patients with multiple myeloma who are receiving investigational chimeric antigen receptor (CAR) T-cell therapy can benefit multiple domains, according to research presented at the 49th Annual Oncology Nursing Society Congress. Ashlee You, RN, BSN, OCN, BMTCN, of Mount Sinai Health System, and colleagues conducted the research. They explained why creating a management plan for patients receiving investigational CAR-T therapies in clinical trials was important. ...